A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
NCT ID: NCT02429271
Last Updated: 2019-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
336 participants
INTERVENTIONAL
2015-08-31
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention
NCT01738100
Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
NCT02798874
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
NCT02808767
Ticagrelor for PCI Post Thrombolysis
NCT01930591
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT01463163
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ticagrelor
1st day 270 mg \& from then onwards 180 mg per day
Ticagrelor
Percutaneous Coronary Intervention (PCI)
Coronary Angiography
Clopidogrel
1st day 300 mg \& from then onwards 75 mg per day
Clopidogrel
Percutaneous Coronary Intervention (PCI)
Coronary Angiography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ticagrelor
Clopidogrel
Percutaneous Coronary Intervention (PCI)
Coronary Angiography
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male and female subjects, 18-75 years of age (both inclusive).
3. STEMI eligible for thrombolysis
4. Inability to perform primary PCI, because of transport time in centers carrying out primary PCI lasting more than two hours
5. Ability of transportation in 3-24 hours after thrombolysis in order to perform coronary angiography and PCI. This period may be extended for reasons of extreme importance up to 72 hours at the latest.
Exclusion Criteria
2. Pre-treatment with any inhibitor of the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) within the 7-day period prior to randomization.
3. Cardiogenic shock - according to Killip classification - class 4.
4. Suspicion or evidence of mechanical complication, including mitral valve dysfunction, ventricular septal rupture, and rupture of the left ventricle.
5. Current use of warfarin or other anticoagulant drug.
6. Known multivessel coronary artery disease not suitable for revascularization.
7. Any contraindication to thrombolytic therapy -Central nervous system damage or neoplasms or atrioventricular malformation -Recent major trauma/surgery/head injury (within the preceding 3 weeks) -Gastrointestinal bleeding within the past month -Known bleeding disorder (excluding menses) -Aortic dissection -Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture).
8. Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.
9. Any kind of stroke in the past year or haemorrhagic stroke ever.
10. Severe uncontrolled hypertension (\>180/110 mmHg) prior to randomisation.
11. Prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) in the last 2 weeks.
12. Known thrombocytopenia defined as platelet count of \<100,000/mm3.
13. Known anemia (hemoglobin \[Hb\] \<10 gr/dL).
14. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
15. Chronic dialysis or known chronic renal failure (glomerular filtration rate (GFR)\<30 ml/min/1.73m2).
16. Known moderate or severe hepatic impairment.
17. Severe uncontrolled chronic obstructive pulmonary disease.
18. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, grapefruit juice over 1 litre daily), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
19. Concomitant use of drugs that are metabolized through cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) (omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol).
20. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree atrioventricular (AV) block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
21. Any known contraindication to clopidogrel, Acetylsalicylic Acid (ASA), or ticagrelor.
22. Current pregnancy, active lactation or parturition (childbirth) within the previous 30 days; women of childbearing potential must have a negative urine pregnancy test, or use a medically accepted method of birth control.
23. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the completion of study participation.
24. Any non-cardiac condition with life expectancy less than 1 year.
25. Inability to adhere to the follow-up requirements or any other reason or condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Cardiovascular Research Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital of Heraklion Venizeleio-Pananeio
Heraklion, Crete, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hamilos M, Kanakakis J, Anastasiou I, Karvounis C, Vasilikos V, Goudevenos J, Michalis L, Koutouzis M, Tsiafoutis I, Raisakis K, Stakos D, Hahalis G, Vardas P; Collaborators. Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial. EuroIntervention. 2021 Feb 19;16(14):1163-1169. doi: 10.4244/EIJ-D-20-00268.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5130C00137
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.